Techniques in Transapical AVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:

Slides:



Advertisements
Similar presentations
Alternate Access Transcatheter Aortic Valve Replacement (TAVR): A single-sites experience with a viable treatment option for extreme risk patients Zachary.
Advertisements

” سبحانك لا علم لنا إلا ما علمتنا إنك أنت العليم الحكيم “
TAVR. Global and US Data. Pichard,
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) 95 th Annual Meeting of the AATS Seattle, WA Jensen HA, Condado JF, Devireddy C, Binongo JN,
University Heart Center Hamburg
AATS Annual Meeting 2015 | Seattle, WA | April 27, 2015 Appropriate Patient Selection or Healthcare Rationing? Lessons from Surgical Aortic Valve Replacement.
TAVR Pearls Addressing the Shortcomings of the Current TAVR Generation
A shifting paradigm of care: Advances in transcatheter heart valve procedures Sandra Lauck MSN, RN, CCN(C) Clinical Nurse Specialist, Arrhythmia Management.
PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.
Techniques in Valve-in-Valve TAVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.
TCT 2015 | San Francisco | October 15, 2015 Howard C. Herrmann, MD on behalf of The PARTNER II Trial Investigators SAPIEN 3: Evaluation of a Balloon- Expandable.
Incidence and Outcomes of Valve Hemodynamic Deterioration in Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: A Report from the Society.
REGISTRY APPROACHES in DEVICE SURVEILLANCE Fred H. Edwards, MD Director, STS Research Center Emeritus Professor, University of Florida.
M.H. Nezafati Associate Professor of Cardiac Surgery
Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D., D. Craig Miller, M.D., Jeffrey W. Moses, M.D., Lars G. Svensson, M.D., Ph.D., E. Murat.
Lessons from PARTNER I (A & B) CRT, Washington DC, Feb 5, 2012
TAVR in Patients With Chronic Kidney Disease
Lessons Learned from the TVT Registry Experience
Patient Eligibility for Commercial TAVR in the US
Extending the Boundaries of TAVR: Future Directions
Trans- catheter aortic valve replacement vs
Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients Vinod H. Thourani, MD on behalf of the PARTNER Trial Investigators Professor.
Anita W. Asgar MD, FRCPC, FACC Montreal Heart Institute
Volume 385, Issue 9986, Pages (June 2015)
Volume 387, Issue 10034, Pages (May 2016)
Are we ready to perform TAVI in Intermediate Risk Patients?
A report from the STS/ACC TVT Registry
Structural Heart Live Cases
TAVR-Endocarditis Tarek Chami, MD
Joseph E. Bavaria, M.D. Roberts-Measey Professor and
TAVR – The Trans-carotid Approach
Review of the Latest OUS Data from the Self-Expanding Valve Studies
TAVR Requirements for the Cath Lab
TAVR in Patients with Chronic Lung Disease
Early Feasibility Studies Investigator Perspective
Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators
Insights from the NCDR® STS/ACC TVT Registry.
Niv Ad, MD Chief, Cardiac Surgery Professor of Surgery, VCU
Ten-year trends in heart valve replacement operations
Annual Outcomes With Transcatheter Valve Therapy
University Heart Center Hamburg
Annual Outcomes With Transcatheter Valve Therapy
The Association of Transcatheter Aortic Valve Replacement Availability and Hospital Aortic Valve Replacement Volume and Mortality in the United States 
Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Prior Coronary Artery Bypass Graft Operation: A PARTNER Trial Subgroup Analysis 
Getting the 411 on TAVR Trials
Nat. Rev. Cardiol. doi: /nrcardio
A comprehensive review of the PARTNER trial
Transatlantic editorial on transcatheter aortic valve replacement
Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.
Transcatheter mitral valve therapy: The event horizon
Impact of Preoperative Chronic Kidney Disease in 2,531 High-Risk and Inoperable Patients Undergoing Transcatheter Aortic Valve Replacement in the PARTNER.
Ten-year trends in heart valve replacement operations
The relative performance characteristics of the logistic European System for Cardiac Operative Risk Evaluation score and the Society of Thoracic Surgeons.
Transapical Aortic Valve Replacement for Severe Aortic Stenosis: Results From the Nonrandomized Continued Access Cohort of the PARTNER Trial  Todd M.
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
2016 Annual Report of The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry  Frederick L. Grover, MD, Sreekanth.
Vinod H. Thourani, MD, Hanna A
Simultaneous transapical transcatheter aortic and mitral valve replacement in a high-risk patient with a previous mitral bioprosthesis  Adil H. Al Kindi,
Transcatheter aortic valve replacement in intermediate-risk patients
Alternative access for balloon-expandable transcatheter aortic valve replacement: Comparison of the transaortic approach using right anterior thoracotomy.
Transcatheter aortic valve replacement and surgical aortic valve replacement: Both excellent therapies  J. James Edelman, MBBS(Hons), PhD, Vinod H. Thourani,
Vinod H. Thourani, MD, Hanna A
Outcomes of Patients With Severe Chronic Lung Disease Who Are Undergoing Transcatheter Aortic Valve Replacement  Rakesh M. Suri, MD, DPhil, Brian C. Gulack,
The Association of Transcatheter Aortic Valve Replacement Availability and Hospital Aortic Valve Replacement Volume and Mortality in the United States 
Kreton Mavromatis, MD, Vinod H
Development and Application of a Risk Prediction Model for In-Hospital Stroke After Transcatheter Aortic Valve Replacement: A Report From The Society.
Commentary: When a choice is not an echo
Racing to the Rubicon  Michael J. Reardon, MD, Vinod H. Thourani, MD 
Presentation transcript:

Techniques in Transapical AVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director: Structural Heart and Valve Center Emory University School of Medicine AATS April 2015

Disclosures Edwards Lifesciences –Emory Co-PI: PARTNER 1 and 2 –National Co-PI: PARTNER 2 (SAPIEN 3 Trial) with Dr. Susheel Kodali St. Jude Medical –Emory PI Portico Trial, Structural Heart Advisory board Boston Scientific –Emory PI: REPRISE Trial –Advisory Board, Executive Comm (Lotus Valve Trial) Medtronic –Emory PI: SURTAVI Trial Jenavalve –National Co-PI with Dr. Martin Leon Abbott Medical –Emory Co-PI: Coapt Trial Apica Cardiovascular –IP, co-founder

In 2015

Transapical and Transaortic Transcatheter Aortic Valve Replacement in the United States Thourani, Jensen, Babaliaros, Suri, Vemulapalli, Dai, Brennan, Rumsfeld, Edwards, Tuzcu, Svensson, Szeto, Herrmann, Kirtane, Kodali, Cohen, Lerakis, Devireddy, Sarin, Carroll, Holmes, Grover, Williams, Maniar, Shahian, and Mack On behalf of the ACC/STS TVT Database Team 51 st Annual Meeting of the STS January 26, 2015

Access Site Source: STS/ACC TVT Registry (7/1/2012-6/30/2014 )

MortalityOverall N=4,953 TA TAVR (N=4,085) TAo TAVR (N=868) P value 30 Day (%) Month (%) Year (%)

Single-lumen intubation Single-lumen intubation TEE TEE Foley catheter, translucent defib pads Foley catheter, translucent defib pads Small roll parallel to spine behind L scapula Small roll parallel to spine behind L scapula 5-6 cm 5 th - 6 th intercostal anterolateral thoracotomy 5-6 cm 5 th - 6 th intercostal anterolateral thoracotomy 6F access to femoral art 6F access to femoral art Pacing wire via femoral vein Pacing wire via femoral vein Lidocaine 100mg Lidocaine 100mg Heparin > ACT 250 seconds Heparin > ACT 250 seconds Transapical Technique

Transapical AVR is: Transapical AVR is: Direct and antegrade Direct and antegrade Potential for minimal embolic neurologic events Potential for minimal embolic neurologic events No limitation to sheath diameter No limitation to sheath diameter Expeditious and less time consuming Expeditious and less time consuming Minimizing radiation Minimizing radiation Minimizing contrast to the elderly patient Minimizing contrast to the elderly patient Applicable in all patients Applicable in all patients Summary

Need for TA Access in the Future The TMVR is Coming

It allows minimal morbidity and mortality when careful and thoughtful surgical technique is followed It allows minimal morbidity and mortality when careful and thoughtful surgical technique is followed Success can only be achieved with a collaborative and dedicated team Success can only be achieved with a collaborative and dedicated team Conclusions

Thank You Vinod H. Thourani, MD